Actuate Therapeutics Stock Soars 15.46% on Positive Phase 2 Trial Results

On June 2, 2025, Actuate's stock surged by 15.46% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Actuate Therapeutics recently presented topline data from its Phase 2 trial of Elraglusib at the ASCO 2025 Annual Meeting. The trial, known as Actuate-1801 Part 3B, met its primary endpoint by demonstrating a clinically meaningful increase in median overall survival, rising from 7.2 months to 10.1 months. This positive outcome has been a key driver behind the recent surge in the company's stock price.

Elraglusib is being developed as a potential monotherapy and as part of combination therapy for pancreatic cancer and Ewing sarcoma. The promising results from the Phase 2 trial have reinforced investor confidence in the drug's potential, contributing to the stock's upward momentum.

The trial also showed a doubling of the 1-year survival rate in the first-line treatment of pancreatic cancer, further highlighting the efficacy of Elraglusib. This development has positioned Actuate Therapeutics as a leader in the field of oncology, with its innovative approach to cancer treatment gaining recognition and support from the medical community.